Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Digitally created image of brain in skull

ForeFront

RESEARCH CENTRE

About us

ForeFront provides a unique combination of clinical and laboratory-based research which together aim to unravel the mechanisms behind frontotemporal dementia (FTD) and motor neurone disease (MND) and help to develop effective treatments.

ForeFront comprises two government funded research groups across four themes:

FTD and MND NHMRC Program grant

  1. Neuropathology
  2. Animal modelling and cellular/molecular biology
  3. Neurological research clinics

Memory node of the ARC Centre of Excellence in Cognition and its Disorders

  1. Cognition and neuroimaging

Who’s involved?

Neuropathology

What regions and cell types are vulnerable? What proteins are affected?

Prof Glenda Halliday and Professor Jillian Kril

Animal modelling and cellular/molecular biology

What proteins are toxic and how do they cause pathogenesis? What cells are vulnerability and how can we prevent this?
Professor Jürgen Götz and Assoc. Professor Lars Ittner

Clinical

How does the disease spread through the brain? How can we develop identification tools and test symptomatic treatments?

Prof John Hodges and Prof Matthew Kiernan

Cognition and neuroimaging

What brain functions are impaired? What brain areas are impaired and which functions do they subserve?

Assoc Professor Olivier Piguet and Dr Michael Hornberger

For more information on the clinical aspects of these disease click here

For more information on the laboratory-based research on these diseases click here

 

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

During three decades on Australian television, two simple words brought us to attention.

‘Hello daaaahling’. Outrageous, flamboyant, iconic – Jeanne Little captivated Australians everywhere with her unique style, cockatoo shrill voice and fashion sense. "Mum wasn't just the life of the party, she was the party.” Katie Little, Jeanne’s daughter remembers. This icon of Australian television brought a smile into Australian homes. Tragically, today Jeanne can't walk, talk or feed herself. She doesn't recognise anyone, with a random sound or laugh the only glimpse of who she truly is. Jeanne Little has Alzheimer's disease. The 1,000 Brains Study NeuRA is very excited to announce the 1,000 Brains Study, a ground-breaking research project to identify the elements in our brains that cause life-changing neurodegenerative diseases like Alzheimer’s, Parkinson’s and other dementias. This study will focus on the key unresolved question: why do some of us develop devastating neurodegenerative diseases, while others retain good brain health? The study will compare the genomes of people who have reached old age with healthy brains against the genomes of those who have died from neurodegenerative diseases, with post mortem examination of brain tissue taking place at NeuRA’s Sydney Brain Bank. More information on the study can be found here. Will you please support dementia research and the 1,000 Brains Study and help drive the future of genetics research in Australia? https://youtu.be/q7fTZIisgAY
APPEAL

What is the analgesic effect of EEG neurofeedback for people with chronic pain? A systematic review

Researchers: A/Prof Sylvia Gustin, Dr Negin Hesam-Shariati, Dr Wei-Ju Chang, A/Prof James McAuley, Dr Andrew Booth, A/Prof Toby Newton-John, Prof Chin-Teng Lin, A/Prof Zina Trost Chronic pain is a global health problem, affecting around one in five individuals in the general population. The understanding of the key role of functional brain alterations in the generation of chronic pain has led researchers to focus on pain treatments that target brain activity. Electroencephalographic (EEG) neurofeedback attempts to modulate the power of maladaptive EEG frequency powers to decrease chronic pain. Although several studies provide promising evidence, the effect of EEG neurofeedback on chronic pain is uncertain. This systematic review aims to synthesise the evidence from randomised controlled trials (RCTs) to evaluate the analgesic effect of EEG neurofeedback. The search strategy will be performed on five electronic databases (Cochrane Central, MEDLINE, Embase, PsycInfo, and CINAHL) for published studies and on clinical trial registries for completed unpublished studies. We will include studies that used EEG neurofeedback as an intervention for people with chronic pain. Risk of bias tools will be used to assess methodological quality of the included studies. RCTs will be included if they have compared EEG neurofeedback with any other intervention or placebo control. The data from RCTs will be aggregated to perform a meta-analysis for quantitative synthesis. In addition, non-randomised studies will be included for a narrative synthesis. The data from non-randomised studies will be extracted and summarised in a descriptive table. The primary outcome measure is pain intensity assessed by self-report scales. Secondary outcome measures include depressive symptoms, anxiety symptoms, and sleep quality measured by self-reported questionnaires. Further, we will investigate the non-randomised studies for additional outcomes addressing safety, feasibility, and resting-state EEG analysis.
PROJECT